Friday, July 15, 2016

BRIEF-OncoTherapy Science says first-patient enrollment in Phase I/II clinical study of OTS167

* Says the first patient has been enrolled in Phase I/II

clinical study of OTS167, an MELK-specific inhibitor, for Acute

Myeloid Leukemia

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)